Concepedia

Author

Naseer Qayum

Roche (United Kingdom)

Also Known As

N Qayum, N. Qayum, Naseer Qayum

37

Publications

495

Citations

12

H-Index

14

Concepts

All Affiliations

Roche (United Kingdom)Roche (Switzerland)The Royal Melbourne HospitalPeter MacCallum Cancer CentreThe University of Melbourne
NQ

About

Naseer Qayum is an author at Roche (United Kingdom) specializing in quantitative pharmacology, humoral immunity, and immune regulation.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

20

2

Immunology

1

1

20

3

Pathology

1

1

20

4

Pharmacology

1

1

20

5

Autoimmunity

1

1

20

Naseer Qayum

×

12

Publications

471

Citations

12

H-Index

YearCitations

Tumor Vascular Changes Mediated by Inhibition of Oncogenic Signaling

Naseer Qayum, Ruth J. Muschel, Jae Hong Im,

Cancer Research

2009

145

Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Adam J. Olszewski, Abraham Avigdor, Sunil Babu,

Blood

2020

57

Modulation of the Tumor Microvasculature by Phosphoinositide-3 Kinase Inhibition Increases Doxorubicin Delivery <i>In Vivo</i>

Naseer Qayum, Jae Hong Im, Michael R.L. Stratford,

Clinical Cancer Research

2011

47

Glofitamab in Relapsed/Refractory Mantle Cell Lymphoma: Results From a Phase I/II Study

Tycel Phillips, Carmelo Carlo‐Stella, Franck Morschhauser,

Journal of Clinical Oncology

2024

41

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Tycel Phillips, Michael Dickinson, Franck Morschhauser,

Blood

2022

39

Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Adam J. Olszewski, Abraham Avigdor, Sunil Babu,

Blood

2022

34

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Max S. Topp, Monica Tani, Michael Dickinson,

Blood

2023

24

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Max S. Topp, Monica Tani, Michael Dickinson,

Blood

2022

23

Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.

Michael Dickinson, Andreas Viardot, Reinhard Marks,

Journal of Clinical Oncology

2023

20

GLOBRYTE: A Phase III, Open-Label, Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Tycel Phillips, Matthew J. Matasar, Toby A. Eyre,

Blood

2023

16

Page 1